Contents of this issue
Jane Adam, Yasuyuki Yamashita(Kumamoto University), T Nakaura, S Cirillo, E. Vestita, Vincenzo Tartaglia, Toshinori Hirai(Kumamoto University), Yoshinori Funama(Kumamoto University Hospital), M Petracchini, Yumi Yanaga, Daniele Regge(Candiolo Cancer Institute), Kumaresan Sandrasegaran, S. Gregory Jennings, P Della, Kazuo Awai(Hiroshima University), H T Winer-Muram, Jonathan A. Fletcher(Harvard University), M. Tann, Y. Nakayama, Teresa Gallo, U Ferrando, Mick M. Welling
Cited by 0
Related Papers
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647
Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma
|American Journal Of Pathology|2001|639